Back

Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study

2025-10-29 respiratory medicine Title + abstract only
View on medRxiv
Show abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with limited treatment options. LTI-03 promotes alveolar epithelial cell survival and reduces profibrotic protein expression in experimental models of IPF. In this Phase 1b, placebo-controlled, dose-escalation study, 24 participants with IPF were randomized 3:1 into 2 sequential dose cohorts to LTI-03 (5 or 10 mg/day) or placebo for 14 days (ClinicalTrials.gov: NCT05954988). The primary endpoint was the incidence of treatme...

Predicted journal destinations

1
European Respiratory Journal
44 training papers
#1 32.6%
2
BMJ Open Respiratory Research
32 training papers
Top 0.8% 10.6%
3
ERJ Open Research
36 training papers
Top 0.3% 10.3%
4
Thorax
29 training papers
Top 0.2% 8.9%
5
American Journal of Respiratory and Critical Care Medicine
23 training papers
Top 0.2% 7.3%
6
PLOS ONE
1737 training papers
Top 78% 5.7%
7
Journal of Allergy and Clinical Immunology
15 training papers
Top 0.3% 2.2%
8
JCI Insight
63 training papers
Top 3% 2.2%
9
Scientific Reports
701 training papers
Top 76% 2.2%
10
Frontiers in Immunology
140 training papers
Top 7% 1.7%
11
BMJ Open
553 training papers
Top 54% 1.5%
12
Frontiers in Pharmacology
27 training papers
Top 2% 1.1%
13
Nature Communications
483 training papers
Top 57% 0.8%
14
eClinicalMedicine
55 training papers
Top 5% 0.8%
15
iScience
74 training papers
Top 11% 0.8%
16
Frontiers in Medicine
99 training papers
Top 21% 0.8%
17
Medicine
29 training papers
Top 5% 0.8%
18
Open Forum Infectious Diseases
124 training papers
Top 18% 0.6%
19
Science Translational Medicine
40 training papers
Top 6% 0.5%
20
New England Journal of Medicine
49 training papers
Top 5% 0.5%
21
eLife
262 training papers
Top 63% 0.5%
22
The Lancet Respiratory Medicine
16 training papers
Top 0.8% 0.5%
23
BMC Medicine
155 training papers
Top 41% 0.5%